当前位置:公众访问 >页面
简体中文 / English
1.Screening and Recruitment
1.1.Inclusion Criteria

Age

58

patients with coronary heart disease

Yes

Sign the informed consent

Yes

Risk stratification for patients with low or middle risk

middle risk

1.2.Exclusion Criteria

Patients in one of the following condition are excluded

none

1.3.Basic Information of Subjects

Name

WAWX

gender

people

Height

174 cm

weight

88.3 kg

abdomen circumference

104 cm

left ventricular ejection fraction(LVEF)

59%

stents implanted

No

anamnesis

hypertension
/
arrhythmia

Body Mass Index

29.17 kg/m2

smoking history

No

blood cholesterol level in hospital

3.78 mmol/l

drink history

No

Bad mood performance

anxiety

exercise habit

No

The drug

antiplatelet drug
/
β-Receptor blockers
/
statins

2.baseline index
2.1.Clinical Index

heart rate in anaerobic domain

125 次/分

heart rate in the peak oxygen uptake

125 次/分

blood pressure in Anaerobic domain

136/86 mm/Hg

blood pressure in the peak oxygen uptake

136/86 mm/Hg

the oxygen uptake in the rest

0.312 ml/kg/min

the oxygen uptake in anaerobic threshold

1.315 ml/kg/min

Peak oxygen uptake

1.315 ml/kg/min

target heart rate

100 次/分

Treadmill load

57 w

blood pressure in the rest

73 次/分

blood pressure in the rest

119/84 mm/Hg

2.3.Biomarkers in plasma

Phosphodiesterase 9A

ng/ml

Inflammatory factors

ng/ml

Immune-modulatory marker

ng/ml

left ventricular dysfunction marker

ng/ml

myeloperoxidase

ng/ml

adiponectin

ng/ml

extracellular-matrix remodeling markers

ng/ml

3.At the end of the treatment
3.1.Clinical Index after treatment

heart rate in anaerobic domain

127 次/分

heart rate in the peak oxygen uptake

125 次/分

blood pressure in the rest

159/84 mm/Hg

blood lipid level in Peak oxygen uptake period

136/86 mm/Hg

the oxygen uptake in the rest

0.297 ml/kg/min

the oxygen uptake in anaerobic threshold

1.529 ml/kg/min

Peak oxygen uptake

1.841 ml/kg/min

target heart rate

110 次/分

Treadmill load

89 w

heart rate in the rest

70 次/分

blood pressure in the rest

117/85 mm/Hg

3.2.Biomarkers in plasma after treatment

Phosphodiesterase 9A

ng/ml

Inflammatory factors

ng/ml

Immune-modulatory marker

ng/ml

left ventricular dysfunction marker

ng/ml

myeloperoxidase

ng/ml

adiponectin

ng/ml

extracellular-matrix remodeling markers

ng/ml

4.Follow-up after 3 months

Patients with follow-up of 3 months is discomfort or not

No

stick to exercise or not in the follow-up after 3 months

Yes